Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan

1. A pharmaceutical combination comprising an antibody specifically recognizing CD38 and at least melphalan, wherein said antibody comprises at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions (CDRs) having amino acid sequences represented by SEQ ID NOS: 13, 81, and 15, and wherein said light chain comprises three sequential CDRs having amino acid sequences represented by SEQ ID NOS: 16, 17, and 18, and wherein the antibody and melphalan constituents of the combination are physically separate.

2. The combination of claim 1 , wherein said antibody is a chimeric or humanized antibody.

3. The combination of claim 1 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence selected from the group of SEQ ID NOS: 62 and 64.

4. The combination of claim 1 , wherein said antibody comprises the CDRs of an antibody produced by a hybridoma cell line having deposit number PTA-7670.

5. A pharmaceutical combination comprising an antibody specifically recognizing CD38 and at least melphalan, wherein said antibody consists of: a light chain comprising the amino acid sequence of SEQ ID NO: 62; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 66, and wherein the antibody and melphalan constituents of the combination are physically separate.

6. A method for treating a hematological cancer in a subject, the method comprising administering the pharmaceutical combination of claim 1 to the subject, thereby treating cancer in the subject.

7. The method of claim 6 , wherein said antibody is a chimeric or humanized antibody.

8. The method of claim 6 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence selected from the group of SEQ ID NOS: 62 and 64.

9. The method of claim 6 , wherein said antibody comprises the CDRs of an antibody produced by a hybridoma cell line having deposit number PTA-7670.

10. The method of claim 6 , wherein the constituents of said combination are administered simultaneously.

11. The method of claim 6 , wherein the constituents of said combination are administered spaced out over a period of time.

12. The method of claim 6 , wherein the hematological cancer is multiple myeloma.